An announcement from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available. Jiangxi Rimag Group Co., Ltd. has announced the launch of the world’s first AI-assisted diagnostic product, ...

(Reuters) -Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes to the country's reimbursement ...

After launching its first liquid biopsy service in Europe earlier this year, the cancer test developer Guardant Health is taking new steps to offer its comprehensive genomic profiling technology in ...

Export controls have further tightened existing restrictions on rare earth metals including gadolinium, dysprosium and yttrium.

Danaher Corporation’s DHR Diagnostics segment continues to contribute steadily to its overall performance. The segment’s core revenues increased 2% on a year-over-year basis in the second quarter of ...

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The ...

The company updated its full-year guidance, expecting organic growth of 2% to 4% and adjusted EPS of $4.85 to $4.95, both down 1% from previous guidance. Life Sciences growth expectations remain ...